Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 1,904 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: AstraZeneca Clear all

Conditions: Healthy Participants
Interventions: Baxdrostat, Itraconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Influenza, Healthy
Interventions: Trivalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: South Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Healthy Female Participants
Interventions: Zibotentan, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Bladder Cancer
Interventions: Romidepsin, Durvalumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 97
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 72 more

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Orange, California • Palo Alto, California • Santa Rosa, California + 4 more

Conditions: Renal Impairment
Interventions: AZD0780; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Lake Forest, California • Hialeah, Florida • Orlando, Florida + 1 more

Conditions: Chronic Kidney Disease
Interventions: AZD4248, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Glendale, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Hyperkalemia
Interventions: LOKELMA 5 GM Powder for Oral Suspension; Drug
Lead sponsor: NephroNet, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: La Jolla, California • Lawrenceville, Georgia • Fort Wayne, Indiana + 2 more

Conditions: Sickle Cell Disease
Interventions: Ticagrelor, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Miami, Florida • Chicago, Illinois + 4 more

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 123 Years
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Anchorage, Alaska • Los Alamitos, California • Los Angeles, California + 16 more

Conditions: Advanced Solid Tumors, Cancer, Advanced Solid Malignancies
Interventions: AZD7762, Irinotecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Nashville, Tennessee

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Placebo to formoterol fumarate, Once-daily formoterol fumarate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 40
States / cities: Tucson, Arizona • Fullerton, California • Lakewood, California + 36 more

Conditions: Barrett Esophagus
Interventions: Ablation System plus anti-secretory medication, Sham procedure plus anti-secretory medication; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Orange, California + 15 more

Conditions: Non-small Cell Lung Cancer
Interventions: Ramucirumab, Necitumumab, Osimertinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Gefitinib, MEDI4736; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Tampa, Florida • Houston, Texas • Seattle, Washington

Conditions: Alzheimer's Disease, Insomnia
Interventions: quetiapine; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 55 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions: AZD5213 + pregabalin, Placebo, pregabalin capsules; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 9
States / cities: Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more

Conditions: Haematologic Neoplasms
Interventions: AZD2962; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Miami, Florida • Tampa, Florida • Houston, Texas

Conditions: Healthy Participants
Interventions: AZD5004, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy Subjects
Interventions: Auto-injector with exenatide suspension, Syringe with exenatide suspension; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 3,052 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Breast Cancer
Interventions: None (Observational study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Interventions: Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment, Questionnaire Administration; Drug · Biological · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Polycystic Ovary Syndrome, Obesity
Interventions: Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Search by objective public record fields.

A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Ablation of Intestinal Metaplasia Containing Dysplasia

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Quetiapine for the Treatment of Insomnia in Alzheimer's Disease

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants

Autoinjector Device Assessment Study

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)